Protagonist Therapeutics Inc.: Business Overview, Financials & Competitive Analysis
Protagonist Therapeutics Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage biotech with two near-term regulatory catalysts, strong cash runway, and blockbuster potential in validated therapeutic areas. Protagonist remains a high-conviction buy, driven by late-stage assets icotrokinra and rusfertide approaching regulatory milestones in 2026. The company has strong financial backing and near-term catalysts, though execution risk remains significant given.
What is Protagonist Therapeutics Inc.'s industry? Protagonist Therapeutics Inc. (protagonist-inc.com) operates in Biopharmaceutical Development. AskCyborg classifies Protagonist Therapeutics Inc. under Biopharmaceutical Development in its company registry.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on peptide-based therapies targeting validated pathways in immunology and inflammation, hematology and metabolic diseases. The company has...
Cyborg Score thesis
Clinical-stage biotech with two near-term regulatory catalysts, strong cash runway, and blockbuster potential in validated...
Read the full analyst-debate transcript →Get the Latest Protagonist Therapeutics Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeProtagonist Therapeutics Inc. Overview
Pro stress-test →Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on peptide-based therapies targeting validated pathways in immunology and inflammation, hematology and metabolic diseases. The company has an advanced and diversified clinical pipeline anchored by two potential blockbuster assets, icotrokinra and rusfertide, both of which have New Drug Applications submitted between July and December 2025 for plaque psoriasis and polycythemia vera, respectively.
Strategic Profile
Pro stress-test →The company possesses a proprietary technology platform focused on discovering and developing peptide-based new chemical entities that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. With a robust cash position of $678.8 million, the company has a runway through 2028, positioning it to advance its pipeline toward commercialization.
Competitive Landscape
Pro stress-test →Protagonist operates in the competitive biopharmaceutical space targeting immunological, inflammatory, and hematological conditions. Key competitive areas include other IL-23 antagonists for psoriasis and ulcerative colitis, and treatments for blood disorders. The company's differentiation lies in its proprietary peptide platform enabling oral formulations of traditionally injectable biologics.
Industry Context
Protagonist Therapeutics Inc. operates in Biopharmaceutical Development.
Key facts
Headquarters: Newark, US · Revenue: $5.5M · Market cap: $5.26B